The Path to HCV Elimination: Always Forward

This webinar was recorded on July 28, 2022

Sponsored by Abbvie

An overview of the impact and burden of Hepatitis C virus in the US, treatment landscape, elimination progress, access restrictions and the health economics of curative treatment.

This program will review:

  • Disease state pathophysiology, burden, and impact of Hepatitis C in the US

  • The WHO HCV elimination targets and the progress to date

  • The current treatment landscape and the most recent AASLD/IDSA guideline recommendations for the treatment of HCV

  • The current access of HCV treatments and the health economics of curative treatment

At the end of the program, attendees should be able to:

  • Understand the pathophysiology and organ systems affected by Hepatitis C

  • Recognize the burden and unmet medical needs for patients with HCV

  • Discuss the current treatment guidelines for management of patients with HCV

  • Understand the current access of HCV treatments and the health economics of curative treatment

 

Speakers:

  • Nancy Reau, MD
    Professor, Department of Internal Medicine, Division of Digestive Diseases and Nutrition
    Section Chief of Hepatology & Associate Director of Organ Transplantation
    Rush University Medical Center

  • Avani Joshi, BPharm., PhD
    Director, Medical Payer Strategy
    US Medical Affairs, Abbvie

This webinar is sponsored, developed, and presented by the sponsor.  The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

Abbvie logo